Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Peptides and Peptide Microarrays for Detection and Differentiation of Antibody Responses to Ebola Virus and Other Pathogens., 91773-91774 [2024-27096]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices
MPA, Executive Secretary, NCVHS,
National Center for Health Statistics,
Centers for Disease Control and
Prevention, 3311 Toledo Road,
Hyattsville, Maryland 20782, or via
electronic mail to nmichaelis@cdc.gov;
or by telephone (301) 458–4202.
Summaries of meetings and a roster of
Committee members are available on the
NCVHS website https://ncvhs.hhs.gov/,
where further information including an
agenda and instructions to access the
broadcast of the meeting will be posted.
Should you require reasonable
accommodation, please telephone the
CDC Office of Equal Employment
Opportunity at (770) 488–3210 as soon
as possible.
As
outlined in its Charter, the National
Committee on Vital and Health
Statistics assists and advises the
Secretary of HHS on health data, data
standards, statistics, privacy, national
health information policy, and the
Department’s strategy to best address
those issues. The original authorities of
NCVHS are described at 42 U.S.C. 242k.
Additional authorities were added by
the Health Insurance Portability and
Accountability Act of 1996 (HIPAA,
Pub. L. 104–191, 110 Stat. 1936, Aug.
21, 1996), under which NCVHS advises
the Secretary on administrative
simplification standards, including
those for privacy, security, adoption and
implementation of transaction
standards, unique identifiers, code sets,
and operating rules adopted under the
Patient Protection and Affordable Care
Act (ACA, Pub. L. 111–148, 124 Stat.
119, Mar. 23, 2010). Included in HIPAA
is the statutory reporting requirement
that the Committee submit to Congress
and make public, a report regarding the
implementation of part C of title XI of
the Social Security Act.
Purpose: Topics on the meeting
agenda will include updates from the
Department and the ICD–11 Workgroup.
The Subcommittee on Privacy,
Confidentiality, and Security will
continue its inquiry into and discussion
of Privacy and Security in Health Data
Access. The Subcommittee on
Standards will report on its current and
future activities. The Committee will
reserve time on the agenda for public
comment. Meeting times and topics are
subject to change. Please refer to the
tentative agenda that will be posted on
the NCVHS website at this link https://
khammond on DSK9W7S144PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
18:39 Nov 19, 2024
Jkt 265001
91773
ncvhs.hhs.gov/meetings/full-committeemeeting-22/ for updates.
would constitute a clearly unwarranted
invasion of personal privacy.
Laina Bush,
Deputy Assistant Secretary, Office of Science
and Data Policy, Office of the Assistant
Secretary for Planning and Evaluation.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Lifestyle
change, Biobehavioral Medicine, and Health
Outcomes.
Date: December 12, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Kristen Prentice, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3112,
MSC 7808, Bethesda, MD 20892, (301) 496–
0726, email: prenticekj@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Behavioral
Motor Function.
Date: December 12, 2024.
Time: 11:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Stephanie Christine Nagle
Emmens, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 594–6604, email:
nagleemmenssc@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
[FR Doc. 2024–27049 Filed 11–19–24; 8:45 am]
BILLING CODE 4150–05–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Amended Notice
of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Neurological Disorders and Stroke
Special Emphasis Panel; R13 Review,
November 21, 2024, 10:00 a.m. to
November 22, 2024, 05:00 p.m.,
National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD, 20852 which
was published in the Federal Register
on October 24, 2024, FR Doc. 2024–
24884, 89 FR 85223.
This notice is being amended to
change the dates of this two-day
meeting to December 2, 2024, and
December 3, 2024. The meeting time
remains the same. The meeting is closed
to the public.
Dated: November 14, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–27045 Filed 11–19–24; 8:45 am]
BILLING CODE 4140–01–P
Dated: November 14, 2024.
Bruce A. George,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–27004 Filed 11–19–24; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Center for Scientific Review; Notice of
Closed Meetings
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00102
Fmt 4703
Sfmt 4703
Prospective Grant of Exclusive
License, Inter-Institutional AgreementInstitution Lead: Peptides and Peptide
Microarrays for Detection and
Differentiation of Antibody Responses
to Ebola Virus and Other Pathogens.
National Institutes of Health,
National Institute of Allergy and
Infectious Diseases.
ACTION: Notice.
AGENCY:
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
SUMMARY:
E:\FR\FM\20NON1.SGM
20NON1
khammond on DSK9W7S144PROD with NOTICES
91774
Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices
Human Services, is contemplating the
grant of an exclusive, sublicensable
patent license to The Trustees of
Columbia University in the City of New
York, Columbia Technology Ventures,
located in New York, New York to
practice the inventions embodied in the
patent applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the Technology Transfer
and Intellectual Property Office,
National Institute of Allergy and
Infectious Diseases on or before
December 5, 2024 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Wade Green, Ph.D., Lead
Technology Transfer and Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Suite 2G,
MSC9804, Rockville, MD 20852–9804,
phone number 301–761–7505, or
wade.green@nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: U.S. Provisional
Patent Application Serial No. 68/
428,826, filed November 30, 2022, titled
‘‘Peptides And Peptide Microarrays For
Detection And Differentiation Of
Antibody Responses To Ebola Virus
And Other Pathogens’’ (HHS Reference
No. E–028–2024–0–US–01) and
International Patent Application No.
PCT/US23/81625, filed on November
29, 2023, titled ‘‘Peptides And Peptide
Microarrays For Detection And
Differentiation Of Antibody Responses
To Ebola Virus’’ (HHS Reference No. E–
028–2024–0–PC–01). All rights in these
inventions have been assigned to The
Trustees of Columbia University in the
City of New York, Columbia Technology
Ventures and the Government of the
United States of America.
The prospective patent license will be
for the purpose of consolidating the
patent rights with The Trustees of
Columbia University in the City of New
York, Columbia Technology Ventures,
the co-owner of said rights, for
commercial development and
marketing. Consolidation of these coowned rights is intended to expedite
development of the invention,
consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212.
The prospective interinstitutional
agreement will include an exclusive
license for NIAID’s rights in these
VerDate Sep<11>2014
18:39 Nov 19, 2024
Jkt 265001
jointly owned patents. It will be
sublicensable, and any sublicenses
granted by The Trustees of Columbia
University in the City of New York
Columbia Technology Ventures will be
subject to the provisions of 37 CFR part
404.
The subject patent rights are related to
novel peptides that enable specific and
sensitive serological detection of
adaptive immune responses to a wide
range of clinically important high threat
pathogens circulating in sub-Saharan
Africa on a wide range of platforms.
These assays allow identification of
individuals who have been immunized
and/or infected with filoviruses.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and may be granted
unless within fifteen (15) days from the
date of this published notice, the
National Insitute of Allergy and
Infectious Diseases receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 15, 2024.
Jeremiah D. Mitzelfelt,
Acting Deputy Director, Technology Transfer
and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases.
[FR Doc. 2024–27096 Filed 11–19–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Tissue Chips in Space 2.0.
Date: February 13–14, 2025.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Center for Advancing
Translational Sciences, National Institutes of
Health, 9609 Medical Center Drive, Bethesda,
MD 20892 (Virtual).
Contact Person: Alumit Ishai, Ph.D.,
Scientific Review Officer, Office of Grants
Management and Scientific Review, National
Center for Advancing Translational Sciences,
National Institutes of Health, 9609 Medical
Center Drive, Suite 1E504, Bethesda, MD
20892, (301) 827–5819, alumit.ishai@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: November 14, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–27046 Filed 11–19–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting.
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\20NON1.SGM
20NON1
]]>Agencies
[Federal Register Volume 89, Number 224 (Wednesday, November 20, 2024)]
[Notices]
[Pages 91773-91774]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-27096]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License, Inter-Institutional
Agreement-Institution Lead: Peptides and Peptide Microarrays for
Detection and Differentiation of Antibody Responses to Ebola Virus and
Other Pathogens.
AGENCY: National Institutes of Health, National Institute of Allergy
and Infectious Diseases.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and
[[Page 91774]]
Human Services, is contemplating the grant of an exclusive,
sublicensable patent license to The Trustees of Columbia University in
the City of New York, Columbia Technology Ventures, located in New
York, New York to practice the inventions embodied in the patent
applications listed in the SUPPLEMENTARY INFORMATION section of this
notice.
DATES: Only written comments and/or applications for a license which
are received by the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases on or
before December 5, 2024 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Wade Green, Ph.D., Lead Technology Transfer and
Patent Specialist, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852-9804, phone number
301-761-7505, or [email protected].
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement: U.S.
Provisional Patent Application Serial No. 68/428,826, filed November
30, 2022, titled ``Peptides And Peptide Microarrays For Detection And
Differentiation Of Antibody Responses To Ebola Virus And Other
Pathogens'' (HHS Reference No. E-028-2024-0-US-01) and International
Patent Application No. PCT/US23/81625, filed on November 29, 2023,
titled ``Peptides And Peptide Microarrays For Detection And
Differentiation Of Antibody Responses To Ebola Virus'' (HHS Reference
No. E-028-2024-0-PC-01). All rights in these inventions have been
assigned to The Trustees of Columbia University in the City of New
York, Columbia Technology Ventures and the Government of the United
States of America.
The prospective patent license will be for the purpose of
consolidating the patent rights with The Trustees of Columbia
University in the City of New York, Columbia Technology Ventures, the
co-owner of said rights, for commercial development and marketing.
Consolidation of these co-owned rights is intended to expedite
development of the invention, consistent with the goals of the Bayh-
Dole Act codified as 35 U.S.C. 200-212.
The prospective interinstitutional agreement will include an
exclusive license for NIAID's rights in these jointly owned patents. It
will be sublicensable, and any sublicenses granted by The Trustees of
Columbia University in the City of New York Columbia Technology
Ventures will be subject to the provisions of 37 CFR part 404.
The subject patent rights are related to novel peptides that enable
specific and sensitive serological detection of adaptive immune
responses to a wide range of clinically important high threat pathogens
circulating in sub-Saharan Africa on a wide range of platforms. These
assays allow identification of individuals who have been immunized and/
or infected with filoviruses.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and may be granted unless within fifteen (15) days from the date of
this published notice, the National Insitute of Allergy and Infectious
Diseases receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: November 15, 2024.
Jeremiah D. Mitzelfelt,
Acting Deputy Director, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-27096 Filed 11-19-24; 8:45 am]
BILLING CODE 4140-01-P
